Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones [Seeking Alpha]
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: Seeking Alpha
The company expects key catalysts in mid-2026: potential FDA Accelerated Approval discussions for SGT-003 and additional data from the phase 1/2 INSPIRE DUCHENNE study. SLDB's capsid design targets improved muscle function and reduced toxicity, with phase 1/2 data showing 58% mean microdystrophin expression and favorable safety. With $236.1M in cash, SLDB is funded into 1H 2027, supporting ongoing DMD and Friedreich's Ataxia programs and multiple upcoming clinical milestones. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Rasi Bhadramani/iStock via Getty Images The last time I spoke about Solid Biosciences Inc. ( SLDB ), it was with respect to a Seeking Alpha article entitled " Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart ". With More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central p
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences (NASDAQ:SLDB) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.MarketBeat
- Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular DystrophyGlobeNewswire
- Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]Yahoo! Finance
- Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswire
- Solid Biosciences (NASDAQ:SLDB) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SLDB
Earnings
- 11/3/25 - Miss
SLDB
Sec Filings
- 2/6/26 - Form 4
- 2/6/26 - Form 4
- 2/6/26 - Form 4
- SLDB's page on the SEC website